Vanguard Group
IOBT

Vanguard Group’s IO Biotech IOBT Stock Holding History

Vanguard Group’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-62,234
Closed -$330K – 4630
2022
Q1 		$330K Sell
62,234
-142,966
-70% -$945K ﹤0.01% 4458
2021
Q4 		$1.31M Buy
+205,200
New +$1.98M ﹤0.01% 4183

Other funds holding IOBT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group's IOBT Position: Q2 2022 in Review

Vanguard Group sold out of IO Biotech (IOBT) in Q2 2022, closing a stake of 62,234 shares — an estimated $330K sold.

Vanguard Group first reported a position in IOBT in Q4 2021 and held it in 2 quarters. The position peaked at $1.31M in Q4 2021. 18 funds tracked by Wall St. Rank hold IOBT as of Q2 2022.

  • Vanguard Group reported no remaining IO Biotech position as of Q2 2022 after selling out during the quarter.
  • Vanguard Group sold 62,234 IO Biotech shares in Q2 2022, an estimated $330K.
  • Vanguard Group first reported a position in IO Biotech in Q4 2021 and held it in 2 quarters.
  • Vanguard Group's IO Biotech position peaked at $1.31M in Q4 2021.
  • 18 funds tracked by Wall St. Rank held IO Biotech as of Q2 2022.

Based on Vanguard Group's 13F filing for Q2 2022, filed 12 Aug 2022.